BRCA2 and neoplasm: Extensive preclinical and clinical trial testing of conventionally administered cisplatin and PARPi combination therapies have shown that PARPis are particularly sensitive and effective against ovarian and breast cancers deficient in BRCA1, BRCA2, and PTEN DNA repair genes.18, 62 The coadministration of PARPis with DNA‐damaging chemotherapies has been extensively shown in clinical trials to prolong tumor‐free survival, improve therapeutic response, and avert the development of resistance due to synergistic effects.